Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition
Gemma A. Wilson, Karla Vuina, Georgina P. Sava, Caroline Huard, Letícia Meneguello, Jasmin Coulombe‐Huntington, Thierry Bertomeu, Rory J. Maizels, Josh Lauring, János Kriston-Vizi, Mike Tyers, Simak Ali, Cosetta Bertoli, Robertus A.M. de Bruin
Abstract
Tumor growth is driven by continued cellular growth and proliferation. Cyclin-dependent kinase 7's (CDK7) role in activating mitotic CDKs and global gene expression makes it therefore an attractive target for cancer therapies. However, what makes cancer cells particularly sensitive to CDK7 inhibition (CDK7i) remains unclear. Here, we address this question. We show that CDK7i, by samuraciclib, induces a permanent cell-cycle exit, known as senescence, without promoting DNA damage signaling or cell death. A chemogenetic genome-wide CRISPR knockout screen identified that active mTOR (mammalian target of rapamycin) signaling promotes samuraciclib-induced senescence. mTOR inhibition decreases samuraciclib sensitivity, and increased mTOR-dependent growth signaling correlates with sensitivity in cancer cell lines. Reverting a growth-promoting mutation in PIK3CA to wild type decreases sensitivity to CDK7i. Our work establishes that enhanced growth alone promotes CDK7i sensitivity, providing an explanation for why some cancers are more sensitive to CDK inhibition than normally growing cells.